I like an IL-17 inhibitor for psoriasis with a current or history of malignancy. IL-17 is involved with cancer neoangiogenesis, so blocking it may have an anti-tumor effect. This hasn’t been studied yet but it makes me feel better that the IL-17 class doesn’t have an increased risk of ca...

I think this needs to be done as part of shared decision-making. I am generally comfortable with all biologics in those with solid organ malignancy. I prefer IL23s in those with lymphoma because IL23s can induce remission. So I will give the loading dose and then dose the patient on demand. I always...